Influence of nutrient correction on adiponectin circulating level and cardiovascular risk factors in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease
Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
International Diabetes Federation (IDF). Diabetes Atlas. 7th ed. Vancouver, Canada, 2015.
Mankovsky BM. Prevalence of the un diagnosed type 2 diabetes mellitus and prediabetes in Ukraine: results of epidemiology research Diapazon. Diabet. Ozhyrinnia. Metabolichnyj syndrom. 2014;5:70-75 (Ukrainian).
Levit Sh., Filippov YI, Gorelyshev AS. Type 2 diabetes mellitus: time to change conception. Diabetes mellitus. 2013;1:91-102 (Russian).
DeFronzo RA. Insulin resistance, lipotoxity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287.
Karachentsev YI, Gorshunska MY, Kravchun NO et al. One nucleotide adiponectin gene polymorphism (+276Т) and expression of insulin resistance state constituents in patients with type 2 diabetes mellitus. Problemy endokrynnoi patologii. 2013;2:7-17 (Ukrainian).
Rydén L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russ J Cardiol. 2014; 107(3):7-61.
Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42(3):641-649.
Setji TL, Holland ND, Sanders LL et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(5):1741-1747.
Pan’kiv VI. Insulin resistance as key pathophysiological mechanism of metabolic syndrome development. Praktychna angiologia. 2012;5/6:24-28 (Ukrainian).
Mykhalchuk LM, Efimov AS. Non-alcoholic fatty liver disease. International Journal of Endocrinology. 2010;2(26):71-82 (Ukrainian).
Bodnar PM, Mykhalchyshyn HP, Kobyliak NM. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Endokrynologia. 2012;17(1):94-101 (Ukrainian).
Sobel BE. Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial. Coron Artery Dis. 2010;21(3):189-198.
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-451.
Ahima RS, Miller RA, Chu Q et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest. 2011;121(6):2518-2528.
Gorshunska MY. Total and high molecular adiponectin weight in patients with type 2 diabetes mellitus taking into account of sex, glycemic control and degree of insulinersistance. Problemy endokrynnoi patologii. 2012;2:91-107 (Ukrainian).
Popovic V, Mattsson AF, Gaillard RC et al. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab. 2010;95(9):4449-4454.
Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006;186(1):5-16.
Shvarz VY. Adiponectin: pathophysiological aspects. Patologicheskaya fiziologia i eksperimentalnaya terapiya. 2009;3:34-38 (Russian).
Kourliouros AK, Gukop P, Hosseini MT et al. Protective effect of epicardial adiponectin release on atrial fibrillation following cardiac surgery. Oxford Journals Medicine & Health Interactive CardioVasc Thoracic Surgery. 2009;9(2):87.
Hotta K, Lange H, Tantillo DJ. еt al. Catalysis of decarboxylation by a preorganized heterogeneous microenvironment: crystal structures of abzyme. J Mol Biol. 2000;302(5):1213-1225.
Yamauchi J, Chan JR, Shooter EM. Neurotrophin 3 activation of TrkC induces Schwann cell migration through the c-Jun N-terminal kinase pathway. Proc Natl Acad Sci USA. 2003;100(24):14421-1446.
Ouchi N, Kihara S, Funahashi T. et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003;14(6):561-566.
Bråkenhielm E, Veitonmäki N, Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101(8):2476-2481.
Barnea MN, Chapnik N, Genzer Y et al. The circadian clock machinery controls adiponectin expression. Mol Cell Endocrinol. 2015;399:284-287.
Song X, Liu X, Cai L, Sheng WY, Gong CX et al. Construction of cTnC-linker-TnI (P) Genes, Expression of Fusion Protein and Preparation of Lyophilized Protein. 2015;32(6):1267-1272.
Ma XQ, Wang M, Xu XX et al. Identification of Volatile Chemical Constituents from Hui Formula "Ha Hei Lili" by GC-MS. 2015;38(10):2176-2179.
Ghoshal K, Bhattacharyya M. Adiponectin: Probe of the molecular paradigm associating diabetes and obesity. World J Diabetes. 2015;6(1):151-166.
Orio FJ, Palomba S, Cascella T et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88(6):2619-2623.
Glintborg D, Andersen M, Hagen C et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. 2006;155(2):337-345.
Risch L, Hoefle G, Saely C et al. Evaluation of two fully automated novel enzyme-linked immunosorbent assays for the determination of human adiponectin in serum. Clin Chim Acta. 2006;373(1-2):121-126.
Kaplan RC, Ho GY, Xue X et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol. Biomarkers Prev. 2007;16(6):1291-1293.
Carmina E, Orio F, Palomba S et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152(3):389-394.
Hill MJ, Kumar S, McTernan PG. Adipokines and the clinical laboratory: what to measure, when and how? J Clin Pathol. 2009;62(3):206-211.
Berg AH, Berg TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-89.
Vega GL, Grundy SM. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes. 2013;10:49-67.
Gorshkov IP, Zoloedov VI. Role of adipocynesin type 2 diabetes mellitus and metabolic syndrome pathogenesis (review). Vestnik novykh meditsinskikh tehnologiy. 2010;17(1):132-134 (Russian).
Solomon SS, Odunusi O, Carrigan D et al. TNF-alpha inhibits insulin action in liver and adipose tissue: A model of metabolic syndrome. Horm Metab Res. 2010; 42(2):115-121.
Lorenzo M, Fernández-Veledo S, Vila-Bedmar R et al. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown. J Anim Sci. 2008;86(14):94-104.
Bremer AA, Jialal L. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes. 2013;9:31-39.
Finucane OM, Reynolds CM, McGillicuddy FC. еt al. Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. Proc Nutr Soc. 2012;71(4):622-633.
Liu Y, Li D, Zhang Y et al. Anthocyanin increases adiponectin secretion and protects against diabetes-related endothelial. Am J Physiol Endocrinol Metab. 2014;306(8):975-988.
Yu LX, Zhou NN, Liu LY еt al. Adiponectin receptor 1 (ADIPOR1) rs1342387 polymorphism and risk of cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(18):15-20.
Correnti JM, Juskeviciute E, Swarup A et al. Pharmacological ceramide reduction alleviates alcohol-induced steatosis and hepatomegaly in adiponectin knockout mice. Am J Physiol Gastrointest Liver Physiol. 2014;306;959-973.
Poltorak VV, Gorshunska MY, Krasova NS. Adiponectin and type 2 diabetes mellitus (pathophysiological aspects as background of antidiabetic pharmacological therapy optimization).Inrernational Journal of Endocrinology. 2014;5:95-104 (Ukrainian).
Uribarri JS, Woodruff S, Goodman S et al. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. Am Diet Assoc. 2010;110(6):911-916.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the. Am J Physiol Renal Physiol. 2005;289:645-659.
O’Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr. 1989;28:211-248.
Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001;56:1-21.
Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glycosylation and glucose-dependent cross-linking of proteins. Biol Chem. 1983;258:9406-9412.
Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Rev. 2001;17:436-443.
Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-497.
Abordo EA, Minhas, Thornalley PJ. Accumulation of alpha-oxoaldehydes during oxidative stress: A role in cytotoxicity. Biochem Pharmacol. 1999;58:641-648.
Fu MX, Requena JR, Jenkins AJ et al. The advanced glycation endproduct N-[carboxymethyl]-lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996;271:9982-9986.
Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104;1287-1291.
Lin RY, Choudhury RP, Cai W et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. 2003;168:213-220.
Zheng F, He C, Cai W. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002;18:224-237.
Lin RY, Reis RY, Reis D, Dore AT еt al. Lowering of dietary advanced glycation endproducts (AGEs) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002;163:303-311.
Peppa M, He C, Hattori M еt al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes. 2003;52:1441-1445.
Hofmann SM, Dong HJ, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002;51:2082-2089.
Sandu O, Song K, Cai W et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes. 2005;54:2314-2319.
Peppa M, Brem H, Ehrlich P. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes. 2003;52:2805-2813.
Uribarri J, Cai N, Peppa M. Circulating glycotoxins and dietary advanced glycation end-products: Two links to inflammatory response oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427-433.
Vlassara H, Uribarri J. Glycoxidation and diabetic complications: Modern lessons and a warning? Rev Endocrin Metab Disord. 2004;5:181-188.
Uribarri J, Goodman S et al. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. Am Diet Assoc. 2010;110(6):1-27.
Kovalyova O, Nyzhegorodtseva O. Left ventricular remodeling and tumor necrosis factor-alpha on hypertension. Eur J Echocardiography. 2002;3(1):15.
Dunaeva IP, Dorosh OG, Karachentsev YI. Nutrient correction in patients with type 2 diabetes mellitus and non-alcoholic fatty liver. East European Scientific Journal. 2016;6:41-53 (Russian).